These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 4038927)

  • 1. Adverse effects of atrial fibrillation and syncope induced by calcium-channel blockers in hypertrophic cardiomyopathy.
    Doiuchi J; Hamada M; Ochi T; Ito T; Kokubu T
    Clin Cardiol; 1985 Mar; 8(3):176-9. PubMed ID: 4038927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter.
    Phillips BG; Gandhi AJ; Sanoski CA; Just VL; Bauman JL
    Pharmacotherapy; 1997; 17(6):1238-45. PubMed ID: 9399606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study.
    Toshima H; Koga Y; Nagata H; Toyomasu K; Itaya K; Matoba T
    Jpn Heart J; 1986 Sep; 27(5):701-15. PubMed ID: 3546779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of hypertrophic cardiomyopathy: relation to pathological mechanisms.
    Kaltenbach M; Hopf R
    J Mol Cell Cardiol; 1985 Jul; 17 Suppl 2():59-68. PubMed ID: 4040978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse effects of nifedipine therapy on hypertrophic obstructive cardiomyopathy.
    Fedor JM; Stack RS; Pryor DB; Phillips HR
    Chest; 1983 Apr; 83(4):704-6. PubMed ID: 6682029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy.
    Rosing DR; Idänpään-Heikkilä U; Maron BJ; Bonow RO; Epstein SE
    Am J Cardiol; 1985 Jan; 55(3):185B-195B. PubMed ID: 3881913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Beta-adrenergic blockers and calcium antagonists in hypertrophic cardiomyopathy].
    Korovina EP
    Klin Med (Mosk); 1998; 76(12):30-5. PubMed ID: 10067289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of calcium channel blockers in hypertrophic cardiomyopathy.
    Lorell BH
    Am J Med; 1985 Feb; 78(2B):43-54. PubMed ID: 4038850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil.
    Lundström T; Rydén L
    J Am Coll Cardiol; 1990 Jul; 16(1):86-90. PubMed ID: 2358610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium channel blockers for heart rate control in atrial fibrillation complicated by congestive heart failure.
    Heywood JT
    Can J Cardiol; 1995 Oct; 11(9):823-6. PubMed ID: 7585281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diastolic function in hypertrophic cardiomyopathy: effects of propranolol and verapamil on diastolic stiffness.
    Hess OM; Grimm J; Krayenbuehl HP
    Eur Heart J; 1983 Nov; 4 Suppl F():47-56. PubMed ID: 6686544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium channel blockers in emergency medicine.
    Young GP
    Ann Emerg Med; 1984 Sep; 13(9 Pt 1):712-22. PubMed ID: 6380352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of acute reduction in left ventricular outflow tract pressure gradient in obstructive hypertrophic cardiomyopathy by disopyramide versus pilsicainide versus cibenzoline.
    Kajimoto K; Imai T; Minami Y; Kasanuki H
    Am J Cardiol; 2010 Nov; 106(9):1307-12. PubMed ID: 21029829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function.
    Pacileo G; De Cristofaro M; Russo MG; Sarubbi B; Pisacane C; Calabrò R
    Can J Cardiol; 2000 Feb; 16(2):146-52. PubMed ID: 10694584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcium antagonists in patients with cardiovascular disease. Current perspectives.
    Winniford MD; Hillis LD
    Medicine (Baltimore); 1985 Jan; 64(1):61-73. PubMed ID: 3880854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the calcium channel-blocking agents diltiazem and verapamil for treatment of feline hypertrophic cardiomyopathy.
    Bright JM; Golden AL; Gompf RE; Walker MA; Toal RL
    J Vet Intern Med; 1991; 5(5):272-82. PubMed ID: 1836234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate-control drugs affect variability and irregularity measures of RR intervals in patients with permanent atrial fibrillation.
    Corino VD; Ulimoen SR; Enger S; Mainardi LT; Tveit A; Platonov PG
    J Cardiovasc Electrophysiol; 2015 Feb; 26(2):137-41. PubMed ID: 25367150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for or against the efficacy of calcium channel blockers for management of hypertrophic cardiomyopathy in cats.
    Bright JM; Golden AL
    Vet Clin North Am Small Anim Pract; 1991 Sep; 21(5):1023-34. PubMed ID: 1683045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium-channel blocking agents.
    Leonard RG; Talbert RL
    Clin Pharm; 1982; 1(1):17-33. PubMed ID: 6764159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertrophic cardiomyopathy--therapy with slow channel inhibiting agents.
    Chatterjee K; Raff G; Anderson D; Parmley WW
    Prog Cardiovasc Dis; 1982; 25(3):193-210. PubMed ID: 6216500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.